Canary Advisors has partnered with Engage Health and Akouos, Inc. (a wholly owned subsidiary of Eli Lilly and Company) to gather meaningful input from families of patients participating in the AK-OTOF-101 clinical trial for the investigational gene therapy AK-OTOF for OTOF-mediated hearing loss. This effort is designed to capture participant experiences and caregiver perspectives separate from data collected within the clinical trial. The insights gathered may help Akouos better understand the participant and caregiver experience and provide a more comprehensive view of AK-OTOF’s impact.